Category: Metastatic Colorectal Cancer

Description

This page contains brief details about the drug capecitabine and cyclophosphamide, it’s indication, dosage & administaration, mechanism of action, related brands with strength, warnings and common side effects.

Date of Approval

Capecitabine and cyclophosphamide is an anticancer drug that belongs to the category of medicines known as antimetabolite and alkylating agents. It was approved in April 1998 to treat Metastatic colorectal cancer.

Mechanism of Action of Capecitabine+Cyclophosphamide

It gets converted into its active form called fluorouracil and interferes with cell signalling, ultimately preventing the multiplication of cancer cells. Capecitabine and cyclophosphamide is prescribed alone and also in combination with other anticancer medications like Docetaxel and Oxaliplatin.

Uses of Capecitabine+Cyclophosphamide

Capecitabine and cyclophosphamide has been developed as a first-line agent to treat advanced and metastatic colorectal cancer and also indicated as an adjunct treatment for stage III colon cancer after the failure of Irinotecan therapy. Capecitabine is also prescribed to treat breast cancer after the failure of taxane-based therapy.

Capecitabine+Cyclophosphamide Dosage available

Capecitabine and cyclophosphamide is available in the form of 500mg tablets. Swallow a tablet with water 30 minutes after food. If you have difficulty swallowing the tablet, seek help from a healthcare provider specialized in the usage of cytotoxic medications to crush or cut the tablet. The accurate dose will be calculated by your healthcare provider and the recommended dosing cycle is twice a day for 2 weeks followed by a 7-days rest period.